TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04940507

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Guided Focused Ultrasound Tumor Ablation and Liquid Biopsy Acquisition
Description: Partial ablation of tumor using ExAblate Neuro 4000 device (InSightec Ltd, Tirat Carmel, Israel) and blood and CSF draws for liquid biopsy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Magnetic Resonance Guided Focused Ultrasound Thalamotomy
Description: Ablation of VIM nucleus of thalamus with MRgFUS using ExAblate Neuro 4000 Device (InSightec Ltd, Tirat Carmel, Israel) and blood draws.
Study: NCT06324279

Intervention type: DEVICE
Intervention: Transvaginal ultrasound
Description: Transvaginal ultrasound will be used to see the presence of cervical sliding sign

Intervention type: DRUG
Intervention: Misoprostol 200mcg Tab
Description: Induction of labor by misoprostol
Study: NCT05754697

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instrument assisted soft tissue mobilization in addition to traditional treatment
Description: The treatment protocol will be two sessions will be given per week for 4 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positional release technique in addition to traditional treatment
Description: The treatment protocol will be two sessions will be given per week for 4 weeks.
Study: NCT04834648

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured Counseling
Description: Structured Counseling, which includes A. Counseling is done by a trained counselor~B. Telephonic Follow up:~C. Development of Fast Track system at the Base Hospital. D. Provide Health Education Material to all Diabetic Patients. E. Referral communication and feedback between referring and referral facility.
Study: NCT06516861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate 20 MG/ML
Description: Administered intravenously with a dose of 30 mg/kg
Study: NCT05035888

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: An initial prophylactic bolus dose of phenylephrine (37.5μg) simultaneous with spinal anesthesia. If the patient did not respond adequately to the current dose (SBP decreased to \< 80% of baseline), the dose was considered to have failed and the subsequent dose for the following patient was increased to the next higher dose level. The dose administered to subsequent patients varied by increments or decrements of 12.5 μg according to the responses of previous patients according to the up-down sequential allocation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: An initial prophylactic bolus dose of norepinephrine (3μg) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 1 μg according to the responses of previous patients according to the up-down sequential allocation.
Study: NCT05464602

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention group Lavender
Description: This group received inhalation aromatherapy 2 drops of lavender oil from aromastone for a total of 3 days, one day before the operation, the day of the operation and the first day after the operation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention group Geranium
Description: This group received inhalation aromatherapy 2 drops of geranium oil from aromastone for a total of 3 days, one day before the operation, the day of the operation and the first day after the operation.
Study: NCT06513208

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac Tromethamine
Description: IV Ketorolac 15mg every 6 hours, x 4 doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV saline as placebo
Study: NCT06547736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A2102 or/and HRS-4642
Description: Drug: SHR-A2102 SHR-A2102 will be administrated per dose level in which the patients are assigned.~Drug: HRS-4642 HRS-4642 will be administrated per dose level in which the patients are assigned.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1904 or/and HRS-4642
Description: Drug: SHR-A1904 SHR-A1904 will be administrated per dose level in which the patients are assigned.~Drug: HRS-4642 HRS-4642 will be administrated per dose level in which the patients are assigned.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811 or/and HRS-4642
Description: Drug: SHR-A1811 SHR-A1811 will be administrated per dose level in which the patients are assigned.~Drug: HRS-4642 HRS-4642 will be administrated per dose level in which the patients are assigned.
Study: NCT05140343

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: KARDIA Mobile ECG Monitoring (KMCM)
Description: The KMCM will be introduced to the patient of the KMCM arm in the outpatient clinic. The activation and configuration will be done together with the physician in the outpatient clinic (installation of the ECG app, enabling heart rate rhythm notification). Patients are requested to acquired ECGs twice weekly plus additional ECGs if symptomatic. In case of symptoms the patient is asked to generate an ECG and communicate the event timely to the investigator and to the treating physician by sending a report through the ECG app. An e-mail account created for the study will be checked at least once a day. The arrhythmia diagnosis will be performed by the clinician based on the ECG information, independently of the arrhythmia classification automatically performed by the device. In case of stronger symptoms of any kind at any time the patient is asked to request medical help regardless of the KMCM notifications. Change of management will be collected.
Study: NCT05217173

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: telerehabilitation
Description: It will start within the first 72 hours of having started with the condition (ankle sprain); They will receive a rehabilitation program using a mobile application (through a digital platform course), which will contain previously recorded videos with exercises that will serve as a guide for rehabilitation activities. The duration of the program will be 30 minutes a day, 5 days a week for 4 weeks
Study: NCT04764526

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protein-enriched ice cream
Description: Offering two protein-enriched ice creams
Study: NCT04767711

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus reuteri ATCC PTA 6475 (L. reuteri 6475)
Description: L.reuteri with cholecalciferol compared to cholecalciferol only.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Oral glucocorticoid 25 mg daily for 7 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisolone
Description: Oral glucocorticoid 25 mg daily for 7 days.
Study: NCT05201651

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine Monohydrate
Description: Participants will orally consume creatine (20 grams in 4×5-gram servings for seven days), followed by 3-g/day during training days. This 3-g/day dosage has been shown to maintain cellular creatine levels.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin Placebo
Description: Participants will orally consume maltodextrin placebo (20 grams in 4×5-gram servings for seven days), followed by 3-g/day during training days.
Study: NCT06464770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine Gluconate
Description: Test Group: the participant's shoulder skin will be treated by the study team with the standard chlorhexidine wash at lower pressure (similar to a gentle wipe) for 30 seconds Control Group: the participant's shoulder skin will be treated by the study team with the standard chlorhexidine wash at higher pressure (similar to a massage) for 30 seconds

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine Gluconate
Description: Test Group: the participant's shoulder skin will be treated by the study team with the standard chlorhexidine wash at lower pressure (similar to a gentle wipe) for 30 seconds Control Group: the participant's shoulder skin will be treated by the study team with the standard chlorhexidine wash at higher pressure (similar to a massage) for 30 seconds
Study: NCT06518915

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: baroloop system
Description: Participants will have the baroloop device implanted for selective stimulation of the vagus nerve.
Study: NCT05485558

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetyl cysteine
Description: 10 mg/kg of N-acetyl cysteine capsules together with their standard antiepileptic drug for 6 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 15 patients will receive standard antiepileptic drug plus placebo capsules for 6 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NAc
Description: 40 mg/kg of N-acetyl cysteine capsules together with their standard antiepileptic drug for 6 months.
Study: NCT05754697

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional treatment
Description: The treatment protocol will be two sessions will be given per week for 4 weeks.
Study: NCT05186740

Intervention type: DEVICE
Group type: OTHER
Intervention: ProVee Urethral Expander System
Description: ProVee Expander is placed in prostatic urethra to relieve obstruction due to BPH.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ProVee Urethral Expander System
Description: ProVee Expander is placed in prostatic urethra to relieve obstruction due to BPH.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Urethral Access Sheath
Description: The Urethral Access Sheath is introduced into the prostatic urethra to simulate the placement of the ProVee Expander.
Study: NCT06174675

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: combined bilateral infraorbital and infratrochlear nerve blocks
Description: Filling the block labelled syringe with 8 mL of bupivacaine 0.25%. Starting with Infraorbital nerve block using an extraoral approach.Inserting a 25-gauge needle laterally to the ipsilateral nostril after palpating the infraorbital ridge to locate the infraorbital foramen. Positioning of the index finger of the non-dominant hand above the infraorbital foramen and advancing the needle feeling it beneath the finger to avoid globe penetration injury. Injecting 3 mL of the study solution slowly after confirming negative aspiration of blood and taking care not to inject into the foramen itself.~Shifting to infratrochlear nerve block by inserting the needle 1 cm above the inner canthus targeting the junction of the orbit and the nasal bone. Injecting 1mL of the study solution after confirming negative aspiration of blood.~Performing contralateral nerve block in the same manner. Applying pressure to four injection points for one minute to prevent hematoma.
Study: NCT05536297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avacincaptad pegol
Description: Intravitreal Injection
Study: NCT05361174

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IOV-4001
Description: A tumor sample is resected from each participant and cultured ex-vivo to manufacture IOV-4001. After lymphodepleting chemotherapy including cyclophosphamide and fludarabine, participant is infused with IOV-4001, and followed by IL-2.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IOV-4001
Description: A tumor sample is resected from each participant and cultured ex-vivo to manufacture IOV-4001. After lymphodepleting chemotherapy including cyclophosphamide and fludarabine, participant is infused with IOV-4001, and followed by IL-2.
Study: NCT05279664

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning (RIC) + Standard of Care for NEC
Description: RIC will consist of 4 cycles of limb ischemia (5 min) followed by reperfusion (5 min), repeated on two consecutive days. An appropriately sized blood pressure cuff (covering 2/3 of the distance between the shoulder and the elbow) will be applied by a trained research fellow or nurse to an arm (or leg if the arm is not available because of medical reasons such as central line insertion). The systolic blood pressure will be measured before the first RIC cycle using a different cuff of same size connected to a monitor. During ischemia time, the cuff will be inflated to a pressure of 15 mmHg above the child's systolic pressure. Neonates in this arm will continue to receive standard of care for NEC.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard of Care for NEC
Description: Neonates in this arm (i.e. the control arm) will receive standard of care for NEC.
Study: NCT06555770

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: müzik müdahalesi
Description: One group of patients will be listening to music for 15 minutes during the surgery, while the other group will be applied a stress ball.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: müzik müdahalesi
Description: One group of patients will be listening to music for 15 minutes during the surgery, while the other group will be applied a stress ball.
Study: NCT05663840

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive resistance exercise
Description: Patients with predominant symptoms of cervical dystonia will receive exercise training. Patients will receive progressive resistance exercise focused cervical and shoulder training (PERFECT) plus standard-of-care (SOC) therapy. Resistance training will consist of mainly muscle-strengthening exercises for the neck, shoulder and arms and a few upper trunk muscles. Resistance training will be guided by physical therapists at twice a week schedule for 6 months. These participants will also receive SOC therapy.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Subjects will receive SOC therapy only
Study: NCT04855370

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive hemodynamic measurements
Description: A patient profile will be set up in the Edwards EV1000 clinical platform by inputting the patient's demographic information. One or two Edwards ClearSight finger cuffs will be placed on the index, middle, and/or ring finger on one hand of the patient. A pressure controller will be secured by a forearm strap where the finger cuffs will be connected to the pressure controller. The pressure controller will be connected to the Edwards EV1000 clinical platform monitor. A heart reference sensor (HRS) will be connected to the pressure controller, a finger cuff, and to the patient at heart level. The Edwards EV1000 clinical platform will calibrate the finger probes, then record measurements for 10-30 seconds every 15 minutes for 12 to 24 hours. If two finger probes are available, measurements will alternate between fingers.
Study: NCT04733534

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dasatinib plus Quercetin
Description: Dasatinib (100 mg/day) plus Quercetin (500 mg twice daily) on days 1, 2, 3, 30, 31, 32 taken orally under observation of the study nurse.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fisetin
Description: Fisetin (20mg/kg/day) on days 1, 2, 30 and 31 taken orally under observation of the study nurse. Fisetin will be dispensed based on weight of 20 mg/kg/day on the four separate days.
Study: NCT05891899

Intervention type: OTHER
Intervention: observation
Description: No interventions planned: treatment of patients at the discretion of the treating/responsible physician
Study: NCT06124768

Intervention type: PROCEDURE
Intervention: Percutaneous mechanical thrombectomy (PMT) by the modified approach
Description: The modified approach includes the ipsilateral calf venous access and the contralateral femoral venous access. Through contralateral femoral venous access, a hydrophilic guide wire and a catheter will be crossover through the thrombus side to the distal calf vein. The ipsilateral calf venous access will be punctured under the guidance of ascending venography. A hydrophilic guide wire and a catheter will be used to pass through the thrombus antegrade to the inferior vena cava. Percutaneous mechanical thrombectomy (PMT) catheter will be used to clear the thrombus. After PMT treatment, residual thrombus will be reevaluated by ascending venography. Catheter-directed thrombolysis (CDT) will be conducted if there is residual thrombus. Percutaneous balloon angioplasty (PTA) and stenting will be conducted if there is \>50% stenosis of the diameter of the iliac vein.

Intervention type: PROCEDURE
Intervention: Percutaneous mechanical thrombectomy (PMT) by the traditional approach
Description: The traditional approach will be punctured from the ipsilateral popliteal vein under ultrasound guidance. A hydrophilic guide wire and a catheter will be used to pass through the thrombus antegrade to the inferior vena cava. Percutaneous mechanical thrombectomy (PMT) catheter will be used to clear the thrombus. After PMT treatment, residual thrombus will be reevaluated by ascending venography. Catheter-directed thrombolysis (CDT) will be conducted if there is residual thrombus. Percutaneous balloon angioplasty (PTA) and stenting will be conducted if there is \>50% stenosis of the diameter of the iliac vein.
Study: NCT06516861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine IV
Description: Administered intravenously with a dose of 1.5mg/Kg
Study: NCT06124768

Intervention type: PROCEDURE
Intervention: Percutaneous mechanical thrombectomy (PMT) by the traditional approach
Description: The traditional approach will be punctured from the ipsilateral popliteal vein under ultrasound guidance. A hydrophilic guide wire and a catheter will be used to pass through the thrombus antegrade to the inferior vena cava. Percutaneous mechanical thrombectomy (PMT) catheter will be used to clear the thrombus. After PMT treatment, residual thrombus will be reevaluated by ascending venography. Catheter-directed thrombolysis (CDT) will be conducted if there is residual thrombus. Percutaneous balloon angioplasty (PTA) and stenting will be conducted if there is \>50% stenosis of the diameter of the iliac vein.
Study: NCT06462313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dobutamine
Description: Patients with septic shock in Dobutamine group will be initiated on Dobutamine at 5 mcg/kg/min when electrocardiogram, invasive blood pressure, and oxygen saturation were monitored.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: Norepinephrine was titrated to maintain a mean arterial pressure at 65mmHg or more in both groups.

Intervention type: DRUG
Group type: OTHER
Intervention: Norepinephrine
Description: Norepinephrine was titrated to maintain a mean arterial pressure at 65mmHg or more in both groups.
Study: NCT05968846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection of peptide p5+14 radiolabeled with iodine-124 (124I-AT-01)
Description: 124I-AT-01 (124I-p5+14, iodine-124I evuzamitide) is a a novel iodine-124 (124I) labeled 45 L-amino acid peptide suitable for PET/CT imaging that has been shown to bind systemic amyloid deposits of diverse types in all organs, including the heart. The peptide binds amyloid through multivalent electrostatic interactions with the amyloid fibril and ubiquitous heparan sulfate proteoglycans.
Study: NCT06230965

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Lung protective ventilation strategy
Description: They were divided into 2 groups: traditional ventilation strategy group (control group) and lung protective ventilation strategy group (experimental group), with 30 cases in each group. In the conventional ventilation strategy group, the conventional ventilation strategies were followed: tidal volume （VT）=10-12ml/kg, respiratory rate（f） =12 times/minute, PEEP=0 cmH₂O, fraction of inspired oxygen=0.5; Lung protective ventilation strategies were implemented in the Lung protective ventilation strategy group: VT=6-8ml/kg, f=12 times/min, PEEP=6-8 cm H₂O,fraction of inspired oxygen=0.5 Manual lung reexpansion was performed every 30 minutes after mechanical ventilation (continuous positive airway pressure of 30 cm H₂O for 30 seconds).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lung protective ventilation strategy
Description: They were divided into 2 groups: traditional ventilation strategy group (control group) and lung protective ventilation strategy group (experimental group), with 30 cases in each group. In the conventional ventilation strategy group, the conventional ventilation strategies were followed: tidal volume （VT）=10-12ml/kg, respiratory rate（f） =12 times/minute, PEEP=0 cmH₂O, fraction of inspired oxygen=0.5; Lung protective ventilation strategies were implemented in the Lung protective ventilation strategy group: VT=6-8ml/kg, f=12 times/min, PEEP=6-8 cm H₂O,fraction of inspired oxygen=0.5 Manual lung reexpansion was performed every 30 minutes after mechanical ventilation (continuous positive airway pressure of 30 cm H₂O for 30 seconds).
Study: NCT04700423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moxidectin (8 mg) / albendazole (400 mg)
Description: Combination therapy of moxidectin (8 mg using 2 mg tablets) plus albendazole (Zentel®, 400 mg, single tablet) administered orally at day 0

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ivermectin (200 µg/kg) / albendazole (400 mg)
Description: Combination therapy of ivermectin ((200 µg/kg), 3 mg tablet) plus albendazole (Zentel®, 400 mg, single tablet) administered orally at day 0
Study: NCT06516861

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline solution
Description: Administered intravenously with 20 ml
Study: NCT06294275

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LP-001 Dose 1 (Single)
Description: A single dose of LP-001 (Dose 1) was administered subcutaneously.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LP-001 Dose 2 (Single)
Description: A single dose of LP-001 (Dose 2) was administered subcutaneously.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LP-001 Dose 3 (Single)
Description: A single dose of LP-001 (Dose 3) was administered subcutaneously.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LP-001 Dose 4 (Single)
Description: A single dose of LP-001 (Dose 4) was administered subcutaneously.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LP-001 Dose 5 (Single)
Description: A single dose of LP-001 (Dose 5) was administered subcutaneously.
Study: NCT04700423

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALBENDAZOLE 400 Mg ORAL TABLET [ZENTEL]
Description: Monotherapy of albendazole (Zentel®, 400 mg, single tablet) administered orally at day 0

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ivermectin (200 µg/kg)
Description: Monotherapy of ivermectin ((200 µg/kg), 3 mg tablet) administered orally at day 0

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: moxidectin (8 mg)
Description: Monotherapy of moxidectin (8 mg, using 2 mg tablets) administered orally at day 0